HIV infection and cardiovascular risk in black South Africans

Cardiovascular Journal of Africa

Volumn 22, Issue 3, 2011, Pages 117-119

  Fourie, C M T ^a   Van Rooyen, J M ^a   Schutte, A E ^a  

^a NORTH WEST UNIVERSITY   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; STAVUDINE; TENOFOVIR; UROKINASE RECEPTOR;

AFRICA; ATHEROSCLEROSIS; BLOOD CLOTTING DISORDER; BODY COMPOSITION; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR FUNCTION; CARDIOVASCULAR RISK; DISEASE ASSOCIATION; DISEASE COURSE; DYSLIPIDEMIA; EDITORIAL; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM INJURY; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; LIFE EXPECTANCY; LIPODYSTROPHY; METABOLIC SYNDROME X; MORTALITY; PRACTICE GUIDELINE; RISK FACTOR; THROMBOSIS; TUBERCULOSIS;

EID: 79959685476     PISSN: 19951892     EISSN: None     Source Type: Journal    
DOI: 10.5830/cvja-2010-050     Document Type: Editorial

References (27)

1. UNAIDS Sub-Saharan Africa. Aids epidemic update. Regional summary 2010. Accessed March 2011. http://www.unaids.org/documents/20101123-GlobalReport-em. pdf.
2. De Gaetano DK, Rabagliati R, Iacoviello L, et al. HIV infection, HAART, and endothelial adhesion molecules: current perspectives. Lancet Infect Dis 2004; 4(4): 213-222.
3. Fisher SD, Miller TL, Lipshultz SE. Impact of HIV and highly active antiretroviral therapy on leukocyte adhesion molecules, arterial inflammation, dyslipidemia, and atherosclerosis. Atherosclerosis 2006; 185(1): 1-11. (Pubitemid 43117545)
4. Riddler SA, Smit E, Cole SR, et al. Impact of HIV infection and HAART on serum lipids in men. J Am Med Asssoc 2003; 289: 2978-2982. (Pubitemid 37430100)
5. Carr A, Cooper DA. Images in clinical medicine. Lipodystrophy associated with an HIV-protease inhibitor. N Engl J Med 1998; 339(18): 1296. (Pubitemid 28496196)
6. Grinspoon SK. Metabolic syndrome and cardiovascular disease in patients with human immunodeficiency virus. Am J Med 2005; 118(Suppl 2): 23S-28S.
7. Constans J, Conri C. Circulating markers of endothelial function in cardiovascular disease. Clin Chim Acta 2006; 368(1-2): 33-47. (Pubitemid 43792418)
8. Hsue PY, Lo JC, Franklin A, et al. Progression of atherosclerosis as assessed by carotid intima-media thickness in patients with HIV infection. Circulation 2004; 109(13): 1603-1608. (Pubitemid 38451715)
9. Glazier JJ, Spears JR, Murphy MC. Interventional approach to recurrent myocardial infarction in HIV-1 infection. J Interv Cardiol 2006; 19(1): 93-98.
10. Abegunde DO, Mathers CD, Adam T, et al. The burden and costs of chronic diseases in low-income and middle-income countries. Lancet 2007; 370:1929-1938. (Pubitemid 350192633)
11. Mayosi BM, Flisher AJ, Lalloo UG, et al. The burden of non-communicable diseases in South Africa. Lancet 2009; 374(9693): 934-947.
12. Sliwa K, Wilkinson D, Hansen C, et al. Spectrum of heart disease and risk factors in a black urban population in South Africa (the Heart of Soweto Study): a cohort study. Lancet 2008; 371(9616): 915-922. (Pubitemid 351375275)
13. South African National AIDS Council. The South African antiretroviral treatment guidelines. 2010. Accessed March 2011. http://www.epiresult.com/ epidemiology-news/23/updated-art-treatment-guidelines-who-and-south-africa.html.
14. Peeters M. The genetic variability of HIV-1 and its implications. Transfus Clin Biol 200; 8(3): 222-225.
15. Jacobs GB, de Beer C, Fincham JE, et al. Serotyping and genotyping of HIV-1 infection in residents of Khayelitsha, Cape Town, South Africa. J Med Virol 2006; 78(12): 1529-1536.
16. Freire E. Overcoming HIV-1 resistance to protease inhibitors. Drug Discovery 2006; 3(2): 281-286. (Pubitemid 44356304)
17. Gaschen B, Taylor J, Yusim K, et al. Diversity considerations in HIV-1 vaccine selection. Science 200; 296: 2354-2360.
18. Simon V, Ho DD, Abdool KQ. HIV/AIDS epidemiology, pathogenesis, prevention, and treatment. Lancet 2006; 368: 489-504. (Pubitemid 44142771)
19. Kruger A, Greeff M, Watson MJ, Fourie CMT. Health care seeking behaviour of newly diagnosed HIV infected people from rural and urban communities in the North West province of South Africa. Afr J Nurs 2009; 11(2): 30-47.
20. Teo K, Chow CK, Vaz M, et al. The Prospective Urban Rural Epidemiology (PURE) study: Examining the impact of societal influences on chronic noncommunicable diseases in low-, middle-, and high-income countries. Am Heart J 2009; 158: 1-7.
21. Fourie CM, van Rooyen JM, Kruger A, Schutte AE. Lipid abnormalities in a never -treated HIV-1 subtype C-infected African population. Lipids 2010, 45(1): 73-80.
22. Seedat YK, Mayet FGH, Latiff GH, et al. Study of risk factors leading to coronary heart disease in urban Zulus. J Hum Hypertens 1993; 7: 569-532.
23. Fourie CM, van Rooyen JM, Pieters M, et al. Is HIV-1 associated with endothelial dysfunction in a population of African ancestry in South Africa? Cardiovasc J Afr 2011; 22(3): 00-00.
24. Domingo P, Cabeza MC, Pruvost A, et al. Relationship between HIV/highly active antiretroviral therapy (HAART)-associated lipodystrophy syndrome and stavudine-triphosphate intracellular levels in patients with stavudine-based antiretroviral regimens. Clin Infect Dis 2010; 50(1): 1033-1040.
25. Andersen O, Eugen-Olsen J, Kofoed K, et al. suPAR associates to glucose metabolic aberration during glucose stimulation in HIV-infected patients on HAART. J Infect 2008; 57(1): 55-63.
26. Sidenius N, Sier CF, Ullum H, Pedersen BK, Lepri AC, Blasi F, et al. Serum level of soluble urokinase-type plasminogen activator receptor is a strong and independent predictor of survival in human immunodeficiency virus infection. Blood 2000; 96(13): 4091-4095.
27. Fourie CM, Van Rooyen JM, Kruger A, et al. Soluble urokinase plasminogen activator receptor (suPAR) is associated with metabolic changes in HIV-1-infected Africans: A prospective study. Inflammation 2011; DOI:10.007/s10753-011-9308-6.